this includes crohn s disease ulcerative colitis rheumatoid arthritis ankylosing spondylitis psoriasis psoriatic arthritis and beh et s disease it is given by slow injection into a vein typically at six to eight week intervals common side effects include infections acute infusion reactions and abdominal pain infliximab is a chimeric monoclonal antibody biologic it works by binding to tnf tnf is a chemical messenger cytokine and a key part of the autoimmune reaction in rheumatoid arthritis infliximab seems to work by preventing tnf from binding to its receptor in the cell infliximab was approved for medical use in the united states in 1998 it was originally developed in mice as a mouse antibody because humans have immune reactions to mouse proteins the mouse common domains were replaced with similar human antibody domains they are monoclonal antibodies and have identical structures and affinities to the target because they are a combination of mouse and human antibody amino acid sequences they are called a chimeric monoclonal antibody in the united states remicade can cost as much as 19 000 per month infliximab biosimilars have been approved in the eu 2013 japan 2014 and usa 2016 three phenotypes or categories of disease are